LON:GSK GSK (GSK) Share Price, News & Analysis GBX 1,390 -15.50 (-1.10%) As of 11:48 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesSustainabilityBuy This Stock About GSK Stock (LON:GSK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GSK alerts:Sign Up Key Stats Today's Range 1,385▼ 1,40650-Day Range 1,323.14▼ 1,545.9452-Week Range 1,242.50▼ 1,678.68Volume9.30 million shsAverage Volume14.33 million shsMarket Capitalization£56.40 billionP/E Ratio22.45Dividend Yield4.32%Price TargetGBX 1,783.33Consensus RatingModerate Buy Company OverviewGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Read More… GSK Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreGSK MarketRank™: GSK scored higher than 78% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGSK has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGSK has only been the subject of 1 research reports in the past 90 days.Read more about GSK's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 22.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.92.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 22.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.49.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GSK. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 4.25%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 96.92%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about GSK's dividend. Sustainability and ESG4.4 / 5Environmental Score-1.56 Short InterestThere is no current short interest data available for GSK. News and Social Media2.7 / 5News Sentiment0.88 News SentimentGSK has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for GSK this week, compared to 5 articles on an average week.Search Interest35 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 190.19% more of their company's stock than they have bought. Specifically, they have bought £27,328.35 in company stock and sold £79,303.77 in company stock.Percentage Held by InsidersOnly 1.61% of the stock of GSK is held by insiders.Percentage Held by Institutions45.33% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GSK's insider trading history. Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Stock News HeadlinesGSK plc (LON:GSK) Insider Wendy Becker Buys 545 SharesJune 24, 2025 | insidertrades.comGSK faces Senator probe for pulling asthma inhaler in U.S.June 29 at 5:56 PM | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.June 30 at 2:00 AM | Brownstone Research (Ad)US senator probes GSK's halt of children's asthma inhalerJune 27 at 4:56 PM | msn.comJonathan Symonds Acquires 1,350 Shares of GSK plc (LON:GSK) StockJune 25, 2025 | americanbankingnews.comGSK Directors Show Confidence with Share PurchasesJune 23, 2025 | tipranks.comGSK Enhances Shareholder Value with Strategic BuybackJune 23, 2025 | tipranks.comGSK and Dalhousie University Collaborate to Address Health Equity Gaps through the GSK Vaccinology and Health Equity Fellowship AwardJune 18, 2025 | finance.yahoo.comSee More Headlines GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at GBX 1,346.50 at the beginning of the year. Since then, GSK stock has increased by 3.2% and is now trading at GBX 1,390. View the best growth stocks for 2025 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) released its earnings results on Wednesday, April, 30th. The company reported $44.90 EPS for the quarter. GSK had a net margin of 8.02% and a trailing twelve-month return on equity of 18.08%. How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include AstraZeneca (AZN), Vodafone Group Public (VOD), Lloyds Banking Group (LLOY), Secure Trust Bank (STB), Barclays (BARC), Meta Platforms (META) and Intel (INTC). Company Calendar Last Earnings4/30/2025Today6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:GSK CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,783.33 High Stock Price TargetGBX 1,900 Low Stock Price TargetGBX 1,600 Potential Upside/Downside+28.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 61.91 Trailing P/E Ratio22.45 Forward P/E Ratio7.90 P/E Growth1.24Net Income£2.50 billion Net Margins8.02% Pretax MarginN/A Return on Equity18.08% Return on Assets9.56% Debt Debt-to-Equity Ratio114.64 Current Ratio0.81 Quick Ratio0.73 Sales & Book Value Annual Sales£31.14 billion Price / Sales1.81 Cash FlowGBX 170.65 per share Price / Cash Flow8.15 Book ValueGBX 329.73 per share Price / Book4.22Miscellaneous Outstanding Shares4,057,829,779Free FloatN/AMarket Cap£56.40 billion OptionableNot Optionable Beta0.31 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (LON:GSK) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.